<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33330841</PMID><DateRevised><Year>2021</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2575-9108</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Dec</Month><Day>11</Day></PubDate></JournalIssue><Title>ACS pharmacology &amp; translational science</Title><ISOAbbreviation>ACS Pharmacol Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors.</ArticleTitle><Pagination><StartPage>1265</StartPage><EndPage>1277</EndPage><MedlinePgn>1265-1277</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acsptsci.0c00130</ELocationID><Abstract><AbstractText>Among the drug targets being investigated for SARS-CoV-2, the viral main protease (M<sup>pro</sup>) is one of the most extensively studied. M<sup>pro</sup> is a cysteine protease that hydrolyzes the viral polyprotein at more than 11 sites. It is highly conserved and has a unique substrate preference for glutamine in the P1 position. Therefore, M<sup>pro</sup> inhibitors are expected to have broad-spectrum antiviral activity and a high selectivity index. Structurally diverse compounds have been reported as M<sup>pro</sup> inhibitors. In this study, we investigated the mechanism of action of six previously reported M<sup>pro</sup> inhibitors, ebselen, disulfiram, tideglusib, carmofur, shikonin, and PX-12, using a consortium of techniques including FRET-based enzymatic assay, thermal shift assay, native mass spectrometry, cellular antiviral assays, and molecular dynamics simulations. Collectively, the results showed that the inhibition of M<sup>pro</sup> by these six compounds is nonspecific and that the inhibition is abolished or greatly reduced with the addition of reducing reagent 1,4-dithiothreitol (DTT). Without DTT, these six compounds inhibit not only M<sup>pro</sup> but also a panel of viral cysteine proteases including SARS-CoV-2 papain-like protease and 2A<sup>pro</sup> and 3C<sup>pro</sup> from enterovirus A71 (EV-A71) and EV-D68. However, none of the compounds inhibits the viral replication of EV-A71 or EV-D68, suggesting that the enzymatic inhibition potency IC<sub>50</sub> values obtained in the absence of DTT cannot be used to faithfully predict their cellular antiviral activity. Overall, we provide compelling evidence suggesting that these six compounds are nonspecific SARS-CoV-2 M<sup>pro</sup> inhibitors and urge the scientific community to be stringent with hit validation.</AbstractText><CopyrightInformation>&#xa9; 2020 American Chemical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Chunlong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yanmei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Townsend</LastName><ForeName>Julia Alma</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagarias</LastName><ForeName>Panagiotis I</ForeName><Initials>PI</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens 15771, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marty</LastName><ForeName>Michael Thomas</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolocouris</LastName><ForeName>Antonios</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens 15771, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI147325</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI157046</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 GM128624</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Pharmacol Transl Sci</MedlineTA><NlmUniqueID>101721411</NlmUniqueID><ISSNLinking>2575-9108</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2020 Sep 16:2020.09.15.299164. doi: 10.1101/2020.09.15.299164</RefSource><PMID Version="1">32995786</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>17</Day><Hour>5</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33330841</ArticleId><ArticleId IdType="pmc">PMC7571300</ArticleId><ArticleId IdType="doi">10.1021/acsptsci.0c00130</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou P.; Yang X. L.; Wang X. G.; Hu B.; Zhang L.; Zhang W.; Si H. R.; Zhu Y.; Li B.; Huang C. L.; Chen H. D.; Chen J.; Luo Y.; Guo H.; Jiang R. D.; Liu M. Q.; Chen Y.; Shen X. R.; Wang X.; Zheng X. S.; Zhao K.; Chen Q. J.; Deng F.; Liu L. L.; Yan B.; Zhan F. X.; Wang Y. Y.; Xiao G. F.; Shi Z. L. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270&#x2013;273. 10.1038/s41586-020-2012-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen K. G.; Rambaut A.; Lipkin W. I.; Holmes E. C.; Garry R. F. (2020) The proximal origin of SARS-CoV-2. Nat. Med. 26, 450&#x2013;452. 10.1038/s41591-020-0820-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0820-9</ArticleId><ArticleId IdType="pmc">PMC7095063</ArticleId><ArticleId IdType="pubmed">32284615</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk C. D.; Laferriere C.; Ardakani A. (2020) A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Front. Pharmacol. 11, 937.10.3389/fphar.2020.00937.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00937</ArticleId><ArticleId IdType="pmc">PMC7317023</ArticleId><ArticleId IdType="pubmed">32636754</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.; Zhou Q.; Li Y.; Garner L. V.; Watkins S. P.; Carter L. J.; Smoot J.; Gregg A. C.; Daniels A. D.; Jervey S.; Albaiu D. (2020) Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent. Sci. 6, 315&#x2013;331. 10.1021/acscentsci.0c00272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.0c00272</ArticleId><ArticleId IdType="pmc">PMC10467574</ArticleId><ArticleId IdType="pubmed">32226821</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J.; Wan Y.; Luo C.; Ye G.; Geng Q.; Auerbach A.; Li F. (2020) Cell entry mechanisms of SARS-CoV-2. Proc. Natl. Acad. Sci. U. S. A. 117, 11727&#x2013;11734. 10.1073/pnas.2003138117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2003138117</ArticleId><ArticleId IdType="pmc">PMC7260975</ArticleId><ArticleId IdType="pubmed">32376634</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M.; Kleine-Weber H.; Schroeder S.; Kruger N.; Herrler T.; Erichsen S.; Schiergens T. S.; Herrler G.; Wu N. H.; Nitsche A.; Muller M. A.; Drosten C.; Pohlmann S. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271&#x2013;280. 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T.; Luo S.; Libby P.; Shi G. P. (2020) Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. Pharmacol. Ther. 213, 107587.10.1016/j.pharmthera.2020.107587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2020.107587</ArticleId><ArticleId IdType="pmc">PMC7255230</ArticleId><ArticleId IdType="pubmed">32470470</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan T. P.; Sims A. C.; Graham R. L.; Menachery V. D.; Gralinski L. E.; Case J. B.; Leist S. R.; Pyrc K.; Feng J. Y.; Trantcheva I.; Bannister R.; Park Y.; Babusis D.; Clarke M. O.; Mackman R. L.; Spahn J. E.; Palmiotti C. A.; Siegel D.; Ray A. S.; Cihlar T.; Jordan R.; Denison M. R.; Baric R. S. (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal365310.1126/scitranslmed.aal3653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aal3653</ArticleId><ArticleId IdType="pmc">PMC5567817</ArticleId><ArticleId IdType="pubmed">28659436</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan T. P.; Sims A. C.; Zhou S.; Graham R. L.; Pruijssers A. J.; Agostini M. L.; Leist S. R.; Schafer A.; Dinnon K. H. 3rd; Stevens L. J.; Chappell J. D.; Lu X.; Hughes T. M.; George A. S.; Hill C. S.; Montgomery S. A.; Brown A. J.; Bluemling G. R.; Natchus M. G.; Saindane M.; Kolykhalov A. A.; Painter G.; Harcourt J.; Tamin A.; Thornburg N. J.; Swanstrom R.; Denison M. R.; Baric R. S. (2020) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb588310.1126/scitranslmed.abb5883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abb5883</ArticleId><ArticleId IdType="pmc">PMC7164393</ArticleId><ArticleId IdType="pubmed">32253226</ArticleId></ArticleIdList></Reference><Reference><Citation>Rut W., Groborz K., Zhang L., Sun X., Zmudzinski M., Pawlik B., M&#x142;ynarski W., Hilgenfeld R., and Drag M. (March 8, 2020) Substrate specificity profiling of SARS-CoV-2 Mpro protease
provides basis for anti-COVID-19 drug design. bioRxiv (Biochemistry), 2020.2003.2007.981928, DOI: 10.1101/2020.03.07.981928.</Citation></Reference><Reference><Citation>Ma C.; Sacco M. D.; Hurst B.; Townsend J. A.; Hu Y.; Szeto T.; Zhang X.; Tarbet B.; Marty M. T.; Chen Y.; Wang J. (2020) Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 30, 678&#x2013;692. 10.1038/s41422-020-0356-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0356-z</ArticleId><ArticleId IdType="pmc">PMC7294525</ArticleId><ArticleId IdType="pubmed">32541865</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z.; Du X.; Xu Y.; Deng Y.; Liu M.; Zhao Y.; Zhang B.; Li X.; Zhang L.; Peng C.; Duan Y.; Yu J.; Wang L.; Yang K.; Liu F.; Jiang R.; Yang X.; You T.; Liu X.; Yang X.; Bai F.; Liu H.; Liu X.; Guddat L. W.; Xu W.; Xiao G.; Qin C.; Shi Z.; Jiang H.; Rao Z.; Yang H. (2020) Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289&#x2013;293. 10.1038/s41586-020-2223-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2223-y</ArticleId><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W.; Zhang B.; Jiang X. M.; Su H.; Li J.; Zhao Y.; Xie X.; Jin Z.; Peng J.; Liu F.; Li C.; Li Y.; Bai F.; Wang H.; Cheng X.; Cen X.; Hu S.; Yang X.; Wang J.; Liu X.; Xiao G.; Jiang H.; Rao Z.; Zhang L. K.; Xu Y.; Yang H.; Liu H. (2020) Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368, 1331&#x2013;1335. 10.1126/science.abb4489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb4489</ArticleId><ArticleId IdType="pmc">PMC7179937</ArticleId><ArticleId IdType="pubmed">32321856</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L.; Lin D.; Sun X.; Curth U.; Drosten C.; Sauerhering L.; Becker S.; Rox K.; Hilgenfeld R. (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 368, 409&#x2013;412. 10.1126/science.abb3405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3405</ArticleId><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco M. D., Ma C., Lagarias P., Gao A., Townsend J. A., Meng X., Dube P., Zhang X., Hu Y., and Kitamura N., et al. (July
27, 2020) Structure and inhibition of
the SARS-CoV-2 main protease reveals strategy for developing dual
inhibitors against Mpro and cathepsin L. bioRxiv (Biophysics), 2020.2007.2027.223727, DOI: 10.1101/2020.07.27.223727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725459</ArticleId><ArticleId IdType="pubmed">33158912</ArticleId></ArticleIdList></Reference><Reference><Citation>Thenin-Houssier S.; de Vera I. M.; Pedro-Rosa L.; Brady A.; Richard A.; Konnick B.; Opp S.; Buffone C.; Fuhrmann J.; Kota S.; Billack B.; Pietka-Ottlik M.; Tellinghuisen T.; Choe H.; Spicer T.; Scampavia L.; Diaz-Griffero F.; Kojetin D. J.; Valente S. T. (2016) Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication. Antimicrob. Agents Chemother. 60, 2195&#x2013;2208. 10.1128/AAC.02574-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02574-15</ArticleId><ArticleId IdType="pmc">PMC4808204</ArticleId><ArticleId IdType="pubmed">26810656</ArticleId></ArticleIdList></Reference><Reference><Citation>de Munnik M.; Lohans C. T.; Lang P. A.; Langley G. W.; Malla T. R.; Tumber A.; Schofield C. J.; Brem J. (2019) Targeting the Mycobacterium tuberculosis transpeptidase LdtMt2 with cysteine-reactive inhibitors including ebselen. Chem. Commun. 55, 10214&#x2013;10217. 10.1039/C9CC04145A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9CC04145A</ArticleId><ArticleId IdType="pmc">PMC6984337</ArticleId><ArticleId IdType="pubmed">31380528</ArticleId></ArticleIdList></Reference><Reference><Citation>Azad G. K.; Singh V.; Mandal P.; Singh P.; Golla U.; Baranwal S.; Chauhan S.; Tomar R. S. (2014) Ebselen induces reactive oxygen species (ROS)-mediated cytotoxicity in Saccharomyces cerevisiae with inhibition of glutamate dehydrogenase being a target. FEBS Open Bio 4, 77&#x2013;89. 10.1016/j.fob.2014.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fob.2014.01.002</ArticleId><ArticleId IdType="pmc">PMC3907691</ArticleId><ArticleId IdType="pubmed">24490132</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender K. O.; Garland M.; Ferreyra J. A.; Hryckowian A. J.; Child M. A.; Puri A. W.; Solow-Cordero D. E.; Higginbottom S. K.; Segal E.; Banaei N.; Shen A.; Sonnenburg J. L.; Bogyo M. (2015) A small-molecule antivirulence agent for treating Clostridium difficile infection. Sci. Transl. Med. 7, 306ra14810.1126/scitranslmed.aac9103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aac9103</ArticleId><ArticleId IdType="pmc">PMC6025901</ArticleId><ArticleId IdType="pubmed">26400909</ArticleId></ArticleIdList></Reference><Reference><Citation>Goins C. M.; Dajnowicz S.; Thanna S.; Sucheck S. J.; Parks J. M.; Ronning D. R. (2017) Exploring Covalent Allosteric Inhibition of Antigen 85C from Mycobacterium tuberculosis by Ebselen Derivatives. ACS Infect. Dis. 3, 378&#x2013;387. 10.1021/acsinfecdis.7b00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.7b00003</ArticleId><ArticleId IdType="pmc">PMC6126352</ArticleId><ArticleId IdType="pubmed">28285521</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S.; Weiner W. S.; Schroeder C. E.; Simpson D. S.; Hanson A. M.; Sweeney N. L.; Marvin R. K.; Ndjomou J.; Kolli R.; Isailovic D.; Schoenen F. J.; Frick D. N. (2014) Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication. ACS Chem. Biol. 9, 2393&#x2013;2403. 10.1021/cb500512z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cb500512z</ArticleId><ArticleId IdType="pmc">PMC4201343</ArticleId><ArticleId IdType="pubmed">25126694</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikawa T.; Schuch G.; Wagner G.; Sies H. (1994) Interaction of ebselen with glutathione S-transferase and papain in vitro. Biochem. Pharmacol. 47, 1007&#x2013;1012. 10.1016/0006-2952(94)90411-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-2952(94)90411-1</ArticleId><ArticleId IdType="pubmed">8147899</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroux F.; Bosc D.; Beghyn T.; Hermant P.; Warenghem S.; Landry V.; Pottiez V.; Guillaume V.; Charton J.; Herledan A.; Urata S.; Liang W.; Sheng L.; Tang W. J.; Deprez B.; Deprez-Poulain R. (2019) Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening. Eur. J. Med. Chem. 179, 557&#x2013;566. 10.1016/j.ejmech.2019.06.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.06.057</ArticleId><ArticleId IdType="pmc">PMC6718346</ArticleId><ArticleId IdType="pubmed">31276900</ArticleId></ArticleIdList></Reference><Reference><Citation>Zmudzinski M., Rut W., Olech K., Granda J., Giurg M., Burda-Grabowska M., Zhang L., Sun X., Lv Z., and Nayak D., et al. (August 31, 2020) Ebselen
derivatives are very potent dual inhibitors of SARS-CoV-2 proteases
- PLpro and Mpro in in vitro studies. bioRxiv (Biochemistry), 2020.2008.2030.273979, DOI: 10.1101/2020.08.30.273979.</Citation></Reference><Reference><Citation>Paranjpe A.; Zhang R.; Ali-Osman F.; Bobustuc G. C.; Srivenugopal K. S. (2014) Disulfiram is a direct and potent inhibitor of human O 6 -methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis 35, 692&#x2013;702. 10.1093/carcin/bgt366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgt366</ArticleId><ArticleId IdType="pmc">PMC3941740</ArticleId><ArticleId IdType="pubmed">24193513</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Sanchez A. G.; Alvarez-Parrilla E.; Martinez-Martinez A.; Aguirre-Reyes L.; Orozpe-Olvera J. A.; Ramos-Soto M. A.; Nunez-Gastelum J. A.; Alvarado-Tenorio B.; de la Rosa L. A. (2016) Inhibition of Urease by Disulfiram, an FDA-Approved Thiol Reagent Used in Humans. Molecules 21, 1628.10.3390/molecules21121628.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules21121628</ArticleId><ArticleId IdType="pmc">PMC6274061</ArticleId><ArticleId IdType="pubmed">27898047</ArticleId></ArticleIdList></Reference><Reference><Citation>Galkin A.; Kulakova L.; Lim K.; Chen C. Z.; Zheng W.; Turko I. V.; Herzberg O. (2014) Structural basis for inactivation of Giardia lamblia carbamate kinase by disulfiram. J. Biol. Chem. 289, 10502&#x2013;10509. 10.1074/jbc.M114.553123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.553123</ArticleId><ArticleId IdType="pmc">PMC4036171</ArticleId><ArticleId IdType="pubmed">24558036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M.-H.; Moses D. C.; Hsieh C.-H.; Cheng S.-C.; Chen Y.-H.; Sun C.-Y.; Chou C.-Y. (2018) Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Res. 150, 155&#x2013;163. 10.1016/j.antiviral.2017.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.12.015</ArticleId><ArticleId IdType="pmc">PMC7113793</ArticleId><ArticleId IdType="pubmed">29289665</ArticleId></ArticleIdList></Reference><Reference><Citation>Dementiev A.; Joachimiak A.; Nguyen H.; Gorelik A.; Illes K.; Shabani S.; Gelsomino M.; Ahn E. E.; Nagar B.; Doan N. (2019) Molecular Mechanism of Inhibition of Acid Ceramidase by Carmofur. J. Med. Chem. 62, 987&#x2013;992. 10.1021/acs.jmedchem.8b01723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.8b01723</ArticleId><ArticleId IdType="pmc">PMC6863082</ArticleId><ArticleId IdType="pubmed">30525581</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber K.; Patel P.; Zhang L.; Evans H.; Westwell A. D.; Fischer P. M.; Chan S.; Martin S. (2008) 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Mol. Cancer Ther. 7, 143&#x2013;151. 10.1158/1535-7163.MCT-07-0486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-07-0486</ArticleId><ArticleId IdType="pubmed">18202017</ArticleId></ArticleIdList></Reference><Reference><Citation>Dom&#xed;nguez J. M.; Fuertes A.; Orozco L.; del Monte-Mill&#xe1;n M.; Delgado E.; Medina M. (2012) Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3&#x3b2; by Tideglusib. J. Biol. Chem. 287, 893&#x2013;904. 10.1074/jbc.M111.306472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.306472</ArticleId><ArticleId IdType="pmc">PMC3256883</ArticleId><ArticleId IdType="pubmed">22102280</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z.; Zhao Y.; Sun Y.; Zhang B.; Wang H.; Wu Y.; Zhu Y.; Zhu C.; Hu T.; Du X.; Duan Y.; Yu J.; Yang X.; Yang X.; Yang K.; Liu X.; Guddat L. W.; Xiao G.; Zhang L.; Yang H.; Rao Z. (2020) Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat. Struct. Mol. Biol. 27, 529&#x2013;532. 10.1038/s41594-020-0440-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-020-0440-6</ArticleId><ArticleId IdType="pubmed">32382072</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratia K.; Pegan S.; Takayama J.; Sleeman K.; Coughlin M.; Baliji S.; Chaudhuri R.; Fu W.; Prabhakar B. S.; Johnson M. E.; Baker S. C.; Ghosh A. K.; Mesecar A. D. (2008) A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl. Acad. Sci. U. S. A. 105, 16119&#x2013;16124. 10.1073/pnas.0805240105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0805240105</ArticleId><ArticleId IdType="pmc">PMC2571001</ArticleId><ArticleId IdType="pubmed">18852458</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R.; Ma C.; Zhang J.; Hu Y.; Diesing J. M.; Marty M. T.; Wang J. (2019) Validating Enterovirus D68&#x2013;2Apro as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68&#x2013;2Apro Inhibitor. J. Virol. 93, e02221-1810.1128/JVI.02221-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02221-18</ArticleId><ArticleId IdType="pmc">PMC6430540</ArticleId><ArticleId IdType="pubmed">30674624</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitas B. T.; Durie I. A.; Murray J.; Longo J. E.; Miller H. C.; Crich D.; Hogan R. J.; Tripp R. A.; Pegan S. D. (2020) Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. ACS Infect. Dis. 6, 2099&#x2013;2109. 10.1021/acsinfecdis.0c00168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00168</ArticleId><ArticleId IdType="pubmed">32428392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C.; Hu Y.; Zhang J.; Musharrafieh R.; Wang J. (2019) A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68. ACS Infect. Dis. 5, 1952&#x2013;1962. 10.1021/acsinfecdis.9b00284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.9b00284</ArticleId><ArticleId IdType="pmc">PMC7167248</ArticleId><ArticleId IdType="pubmed">31532189</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C.; Hu Y.; Zhang J.; Wang J. (2020) Pharmacological Characterization of the Mechanism of Action of R523062, a Promising Antiviral for Enterovirus D68. ACS Infect. Dis. 6, 2260&#x2013;2270. 10.1021/acsinfecdis.0c00383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00383</ArticleId><ArticleId IdType="pmc">PMC8057299</ArticleId><ArticleId IdType="pubmed">32692536</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R.; Kitamura N.; Hu Y.; Wang J. (2020) Development of broad-spectrum enterovirus antivirals based on quinoline scaffold. Bioorg. Chem. 101, 103981.10.1016/j.bioorg.2020.103981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioorg.2020.103981</ArticleId><ArticleId IdType="pmc">PMC7390679</ArticleId><ArticleId IdType="pubmed">32559580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q. A., Kato-Weinstein J., Li Y., Deng Y., Granet R., Garner L., Liu C., Polshakov D., Gessner C., and Watkins S. (2020) Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections. ACS Pharmacol. Transl. Sci. 10.1021/acsptsci.0c00074</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.0c00074</ArticleId><ArticleId IdType="pmc">PMC7447080</ArticleId><ArticleId IdType="pubmed">33062950</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen N. C.; Kim Y.; Liu H.; Galasiti Kankanamalage A. C.; Eckstrand C.; Groutas W. C.; Bannasch M.; Meadows J. M.; Chang K. O. (2018) Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J. Feline Med. Surg. 20, 378&#x2013;392. 10.1177/1098612X17729626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1098612X17729626</ArticleId><ArticleId IdType="pmc">PMC5871025</ArticleId><ArticleId IdType="pubmed">28901812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.; Liu H.; Galasiti Kankanamalage A. C.; Weerasekara S.; Hua D. H.; Groutas W. C.; Chang K. O.; Pedersen N. C. (2016) Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog. 12, e100553110.1371/journal.ppat.1005531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005531</ArticleId><ArticleId IdType="pmc">PMC4814111</ArticleId><ArticleId IdType="pubmed">27027316</ArticleId></ArticleIdList></Reference><Reference><Citation>Sies H.; Parnham M. J. (2020) Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections. Free Radical Biol. Med. 156, 107&#x2013;112. 10.1016/j.freeradbiomed.2020.06.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.06.032</ArticleId><ArticleId IdType="pmc">PMC7319625</ArticleId><ArticleId IdType="pubmed">32598985</ArticleId></ArticleIdList></Reference><Reference><Citation>Men&#xe9;ndez C. A.; Byl&#xe9;hn F.; Perez-Lemus G. R.; Alvarado W.; de Pablo J. J. (2020) Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease. Sci. Adv. 6, eabd034510.1126/sciadv.abd0345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd0345</ArticleId><ArticleId IdType="pmc">PMC7486088</ArticleId><ArticleId IdType="pubmed">32917717</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C. W.; Tee H. K.; Lee M. H.; Sam I. C.; Chan Y. F. (2016) Enterovirus A71 DNA-Launched Infectious Clone as a Robust Reverse Genetic Tool. PLoS One 11, e016277110.1371/journal.pone.0162771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0162771</ArticleId><ArticleId IdType="pmc">PMC5019408</ArticleId><ArticleId IdType="pubmed">27617744</ArticleId></ArticleIdList></Reference><Reference><Citation>Marty M. T.; Baldwin A. J.; Marklund E. G.; Hochberg G. K.; Benesch J. L.; Robinson C. V. (2015) Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles. Anal. Chem. 87, 4370&#x2013;4376. 10.1021/acs.analchem.5b00140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.5b00140</ArticleId><ArticleId IdType="pmc">PMC4594776</ArticleId><ArticleId IdType="pubmed">25799115</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>